Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1172 ARTÍCULOS , VIENDO DEL 1096 AL 1110

Impaired ideomotor limb apraxia in cortical and subcortical dementia: a comparison of Alzheimer's and Huntington's disease

Holl AK, Ille R, Wilkinson L, Otti DV, Hödl E, Herranhof B, Reisinger KM, Müller N, Painold A, Holl EM, Letmaier M, Bonelli RM.

Neurodegener Dis. 2011;8(4):208-15. doi: 10.1159/000322230. Epub 2011 Jan 5.

The role of CREB signaling in Alzheimer's disease and other cognitive disorders

Saura CA, Valero J.

Rev Neurosci. 2011;22(2):153-69. doi: 10.1515/RNS.2011.018.

The ethics of disclosing genetic diagnosis for Alzheimer's disease: do we need a new paradigm?

Arribas-Ayllon M.

Br Med Bull. 2011;100:7-21. doi: 10.1093/bmb/ldr023. Epub 2011 Jun 14.

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development

Ehrnhoefer DE, Wong BK, Hayden MR.

Nat Rev Drug Discov. 2011 Oct 21;10(11):853-67. doi: 10.1038/nrd3556.

Epigenetic treatment of neurological disease

Gray SG.

Epigenomics. 2011 Aug;3(4):431-50. doi: 10.2217/epi.11.67.

The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease

da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, Barreiro EJ, Viegas C Jr.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):251-70. doi: 10.2174/187152711794480429.

Neuronal hemoglobin is reduced in Alzheimer's disease, argyrophilic grain disease, Parkinson's disease, and dementia with Lewy bodies

Ferrer I, Gómez A, Carmona M, Huesa G, Porta S, Riera-Codina M, Biagioli M, Gustincich S, Aso E.

J Alzheimers Dis. 2011;23(3):537-50. doi: 10.3233/JAD-2010-101485.

Insights from Caenorhabditis elegans on the role of metals in neurodegenerative diseases

Martinez-Finley EJ, Avila DS, Chakraborty S, Aschner M.

Metallomics. 2011 Mar;3(3):271-9. doi: 10.1039/c0mt00064g. Epub 2011 Jan 6.

Implication of oncogenic signaling pathways as a treatment strategy for neurodegenerative disorders - contemporary approaches

Sieradzki A, Yendluri BB, Palacios HH, Parvathaneni K, Reddy VP, Obrenovich ME, Gąsiorowski K, Leszek J, Aliev G.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):175-83. doi: 10.2174/187152711794480410.

Pedophilic behavior from brain disease

Mendez M, Shapira JS.

J Sex Med. 2011 Apr;8(4):1092-100. doi: 10.1111/j.1743-6109.2010.02172.x. Epub 2011 Jan 14.

Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer's disease pathology and is independent of tau, Aβ and TDP-43 pathology

Dakson A, Yokota O, Esiri M, Bigio EH, Horan M, Pendleton N, Richardson A, Neary D, Snowden JS, Robinson A, Davidson YS, Mann DM.

Acta Neuropathol. 2011 May;121(5):635-49. doi: 10.1007/s00401-011-0798-y. Epub 2011 Jan 18.

Mitophagy in neurodegeneration: an opportunity for therapy?

Santos RX, Correia SC, Carvalho C, Cardoso S, Santos MS, Moreira PI.

Curr Drug Targets. 2011 Jun;12(6):790-9. doi: 10.2174/138945011795528813.

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

Flood DG, Marek GJ, Williams M.

Biochem Pharmacol. 2011 Jun 15;81(12):1422-34. doi: 10.1016/j.bcp.2011.01.021. Epub 2011 Feb 3.

TDP-43 in aging and Alzheimer's disease - a review

Wilson AC, Dugger BN, Dickson DW, Wang DS.

Int J Clin Exp Pathol. 2011 Jan 30;4(2):147-55.

Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort

Boeve BF, Molano JR, Ferman TJ, Smith GE, Lin SC, Bieniek K, Haidar W, Tippmann-Peikert M, Knopman DS, Graff-Radford NR, Lucas JA, Petersen RC, Silber MH.

Sleep Med. 2011 May;12(5):445-53. doi: 10.1016/j.sleep.2010.12.009. Epub 2011 Feb 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias